Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

INO 4800. 95% efficacy at room temperature storage! pg 14, Table 9
Int. J. Environ. Res. Public Health 2022, 19(4), 2392;
Brazil study
Received: 5 January 2022 / Revised: 9 February 2022 / Accepted: 15 February 2022 / Published: 18 February 2022
7.2.1. DNA Vaccine INO-4800 INO-4800 is a plasmid DNA vaccine developed by Inovio Pharmaceuticals (USA) for preclinical testing within the ferret model of COVID-19. This DNA vaccine encoding the S protein was delivered by electroporation [33]. INO-4800 was able to reduce viral load in non-human primates; rhesus macaque, used as model, that received two doses (1 mg) for 4 weeks of the DNA vaccine showed humoral and cellular immune responses after 13 weeks [38]. The vaccine s+howed effectiveness against both D614 and G614 SARS-CoV-2 variants [38]. The study of safety, tolerability, and immunogenicity of INO-4800 for COVID-19 was tested in healthy volunteers using SARS-CoV-2 spike glycoprotein as antigen.

https://www.researchgate.net/publication/358711697_Classical_and_Next-Generation_Vaccine_Platforms_to_SARS-CoV-2_Biotechnological_Strategies_and_Genomic_Variants